Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ic/ml (chenopodium album pollen extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (chenopodium album pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 0.1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts); allergen extracts 1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts); allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) - solution for injection - active: allergen extracts 0.1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (fraxinus excelsior (33.33%), olea europaea (33.33%), ligustrum vulgare (33.33%) pollen extracts) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 1 ic/ml (plantago lanceolata pollen extract); allergen extracts 1 ic/ml (plantago lanceolata pollen extract); allergen extracts 10 ic/ml (plantago lanceolata pollen extract) - solution for injection - active: allergen extracts 1 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - allergen extracts 10 ic/ml (plantago lanceolata pollen extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (plantago lanceolata pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

alk-abello, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q), dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k) - dermatophagoides farinae 5000 [au] in 1 ml - this product is indicated for the diagnosis and treatment of hypersensitivity in patients with symptoms compatible with dust mite allergy. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. mixtures of standardized mite (d. farinae and d. pteronyssinus) should be considered for treatment of patients who are sensitive to both species. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. there are no known absolute contraindications to immunotherapy. however, a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms and positive skin tests. in most case

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

nelco laboratories, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides farinae 10000 [au] in 1 ml - standardized mite allergenic extracts are intended for use in the diagnosis and therapy of d.farinae and d.pteronyssinus mite allergy, as established by allergy history and skin test reactivity (6,10) . standardized mite extracts are not interchangeable with non standardized mite extracts. to select patients for a confirmation of allergic disease diagnosis and/or treatment with allergen extracts, screening tests should be done using in vivo identification testing methods (i.e. scratch or intradermal testing).(13) standardized mite extract containing equal parts of d.farinae and d.pteronyssinus is intended for therapy only. the use of standardized mites extract is indicated for hypersensitization treatment and may be used as part of the over-all management of the allergic patient. this treatment is particularly to be recommended when a patient's sensitivity to mite has been determined initially by scratch or intradermal skin tests. this product should not be used if the patient has asthma, cardiovascular disea

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

allermed laboratories, inc. - dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q) - dermatophagoides farinae 10000 [au] in 1 ml - standardized mite extract is indicated for use in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy who have established sensitivity to mites by diagnostic skin testing. the use of mite extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook 10 . injections of mite extract should not be administered in the presence of diseases characterized by a bleeding diathesis. immunotherapy should not be started in patients until a specific diagnosis of type i allergy to mite is made by a physician based on skin testing with this product. other contraindications include: extreme sensitivity to mite: determined from previous anaphylaxis following skin testing, immunotherapy, or natural exposure. autoimmune disease: individuals with autoimmune disease maybe at risk, due to the possibility of routine immunizations e

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

antigen laboratories, inc. - dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k), quercus alba pollen (unii: z4y9zsv4kk) (quercus alba pollen - unii:z4y9zsv4kk) - dermatophagoides pteronyssinus 2000 [au] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

antigen laboratories, inc. - dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k), canis lupus familiaris hair (unii: 05s7l91ztr) (canis lupus familiaris hair - unii:05s7l91ztr) - dermatophagoides pteronyssinus 2000 [au] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski